argenx SE

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell argenx SE and other ETFs, options, and stocks.

About ARGX

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. 

CEO
Tim van Hauwermeiren
CEOTim van Hauwermeiren
Employees
1,599
Employees1,599
Headquarters
Amsterdam, Noord-Holland
HeadquartersAmsterdam, Noord-Holland
Founded
2008
Founded2008
Employees
1,599
Employees1,599

ARGX Key Statistics

Market cap
53.04B
Market cap53.04B
Price-Earnings ratio
39.79
Price-Earnings ratio39.79
Dividend yield
Dividend yield
Average volume
357.14K
Average volume357.14K
High today
$863.11
High today$863.11
Low today
$849.53
Low today$849.53
Open price
$851.48
Open price$851.48
Volume
366.38K
Volume366.38K
52 Week high
$934.62
52 Week high$934.62
52 Week low
$510.06
52 Week low$510.06

Stock Snapshot

With a market cap of 53.04B, argenx SE(ARGX) trades at $854.99. The stock has a price-to-earnings ratio of 39.79.

On 2025-12-19, argenx SE(ARGX) stock traded between a low of $849.53 and a high of $863.11. Shares are currently priced at $854.99, which is +0.6% above the low and -0.9% below the high.

The argenx SE(ARGX)'s current trading volume is 366.38K, compared to an average daily volume of 357.14K.

During the past year, argenx SE(ARGX) stock moved between $510.06 at its lowest and $934.62 at its peak.

During the past year, argenx SE(ARGX) stock moved between $510.06 at its lowest and $934.62 at its peak.

ARGX News

Seeking Alpha 1d
Argenx cut to Neutral at Baird after trial setback for Vyvgart

argenx SE (ARGX) traded lower on Thursday as Baird downgraded the Dutch biotech, citing concerns over its valuation following a late-stage trial setback for its...

Argenx cut to Neutral at Baird after trial setback for Vyvgart
TipRanks 3d
Argenx Moves Ahead With Its Phase 2 Study on ARGX-119 for Pediatric SMA

Argenx (ARGX) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...

Benzinga 5d
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Argenx SE (NASDAQ:ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and...

Analyst ratings

86%

of 28 ratings
Buy
85.7%
Hold
10.7%
Sell
3.6%

More ARGX News

TipRanks 6d
Argenx’s Efgartigimod Study: A New Horizon in CIDP Treatment

Argenx (ARGX) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.